Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Esomeprazole with or without Barrett mucosa ablation after endoscopic cure of Barrett adenocarcinoma
2005-006191-35Phase 3Terminated
- Sponsor
- Haisco Pharmaceutical Group Co., Ltd.
- Start
- May 2006
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of esomeprazole in Barrett's esophagus and esophageal adenocarcinoma (EAC) (3 arms), sponsored by Haisco Pharmaceutical Group Co., Ltd. Primary endpoints: Incidence of secondary neoplasia during follow-up, Time to secondary neoplasia and 1 more. Started May 2006; status: terminated.
02
Drugs
esomeprazole
03
Conditions
Barrett's esophagusesophageal adenocarcinoma (EAC)
Beyond the preview
Go deeper on 2005-006191-35.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2005-006191-35.